Lycopene supplementation in rats with metabolic syndrome caused by diet does not significantly change body weight, fat index, or systolic blood pressure. This suggests that lycopene primarily affects metabolic processes rather than weight or blood pressure regulation.
See the scientific wording
In rats with diet-induced metabolic syndrome, lycopene supplementation does not significantly modify body weight, adiposity index, or systolic blood pressure, indicating that its effects are primarily metabolic rather than on weight regulation or blood pressure.
Correlational — new studies may shift this
Randomized trialsOne low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialAnimal
The study found that lycopene helped lower bad fats and raise good fats in the blood, and reduced fat in the liver, but it didn't check whether lycopene affects weight or blood pressure, so it can't say about those parts of the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
In rats with metabolic syndrome, the liver becomes inflamed and insulin-resistant due to a high-sugar, high-fat diet. Lycopene lowers inflammation and oxidative stress in the liver, allowing insulin to work properly again. This improves the liver's ability to process amino acids and fats, reducing fat buildup in the liver and improving blood fat levels. As a result, lycopene improves metabolic health without causing weight loss or changes in blood pressure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Lycopene supplementation in rats with metabolic syndrome caused by diet does not significantly change body weight, fat index, or systolic blood pressure. This suggests that lycopene primarily affects metabolic processes rather than weight or blood pressure regulation.
Mechanism
1 studyLycopene reduces inflammation and oxidative stress in the liver, making insulin work better. This helps the liver process amino acids and fats, lowering fat buildup and improving blood fat levels. These metabolic improvements happen without affecting body weight or blood pressure.
In rats with metabolic syndrome, the liver becomes inflamed and insulin-resistant due to a high-sugar, high-fat diet. Lycopene lowers inflammation and oxidative stress in the liver, allowing insulin to work properly again. This improves the liver's ability to process amino acids and fats, reducing fat buildup in the liver and improving blood fat levels. As a result, lycopene improves metabolic health without causing weight loss or changes in blood pressure.
A high-sugar, high-fat diet induces chronic low-grade inflammation and oxidative stress in the liver, impairing insulin signaling and causing hepatic insulin resistance.
Lycopene supplementation exerts antioxidant and anti-inflammatory effects in the liver, reducing reactive oxygen species and pro-inflammatory cytokines, thereby restoring hepatic insulin sensitivity.
Restored insulin signaling increases the hepatic uptake and catabolism of branched-chain amino acids (BCAAs), providing substrates for energy metabolism and reducing hepatic lipid accumulation.
Lycopene supplementation also activates sphingosine kinase 2 in the liver, increasing the production of sphinganine-1-phosphate (S1P), which promotes fatty acid oxidation and improves hepatic lipid homeostasis.
These combined effects reduce hepatic triglyceride accumulation by 11.9% and improve the plasma lipid profile: triglycerides decrease by 19.5% and HDL-cholesterol increases by 52.6%.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study found that lycopene helped lower bad fats and raise good fats in the blood, and reduced fat in the liver, but it didn't check whether lycopene affects weight or blood pressure, so it can't say about those parts of the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Lycopene Supplementation Effects on Metabolic Syndrome Parameters in Rodent Models
Comprehensive search of databases for controlled animal studies of lycopene supplementation in rodent models of diet-induced metabolic syndrome, with meta-analysis of outcomes (body weight, adiposity index, systolic blood pressure).
Randomized Controlled Trial of Lycopene vs Placebo in Rats with Diet-Induced Metabolic Syndrome
Randomized, placebo-controlled trial with rats fed a high-fat/high-sugar diet to induce metabolic syndrome, then randomized to lycopene supplementation or placebo for a defined period, measuring body weight, adiposity index, and systolic blood pressure at baseline and end.
Prospective Cohort Study of Lycopene Supplementation in Rats with Metabolic Syndrome
Longitudinal observational study of rats with diet-induced metabolic syndrome, some receiving lycopene supplementation and others not, with regular measurements of body weight, adiposity index, and systolic blood pressure.
Controlled Laboratory Experiment of Lycopene Supplementation in Rats with Diet-Induced Metabolic Syndrome
Controlled experiment with two groups of rats (lycopene vs. control) on a high-fat/high-sugar diet, measuring outcomes at multiple time points, with appropriate sample size and statistical analysis.